ReviewJournal of Cancer2017
Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor.
Review in Journal of Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
130 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Efficacy of PD-1/PD-L1 and LAG-3 immune checkpoint inhibitors in the treatment of patients with solid tumor.Frontiers in immunology · 2026Pooled it
- A systematic review of the role of interleukin inhibitors in lichen planus: therapeutic and paradoxical effects.Inflammopharmacology · 2025Pooled it
- Is nivolumab alone or in combination with ipilimumab more effective for treating lung cancer? a meta-analysis.European journal of clinical pharmacology · 2025Pooled it
- Evaluating the efficacy and safety of nivolumab and ipilimumab combination therapy compared to nivolumab monotherapy in advanced cancers (excluding melanoma): a systemic review and meta-analysis.Journal of the Egyptian National Cancer Institute · 2024Pooled it
- Tislelizumab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of advanced non-small cell lung cancer: systematic review and indirect comparison of randomized trials.Frontiers in pharmacology · 2023Pooled it
- Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Markers for Advanced Non-Small-Cell Lung Cancer Treated with Immunotherapy: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2022Pooled it
- Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma.Investigational new drugs · 2024Trial
- Exposure-response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040).Clinical and translational science · 2023Trial
- Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open-label phase 2 trial.Cancer science · 2019Trial
- Molecular interplay of insulin resistance and cancer: advances in monoclonal antibody therapeutics.Cancer biology & therapy · 2026Review
- Association of the PD-L1 CPS With the Efficacy of First-Line Nivolumab Plus Chemotherapy for Unresectable Advanced or Recurrent Gastric Cancer.Cancer medicine · 2026Article
- Understanding the Therapeutic Potential of PD-1 Agonism in Inflammatory and Autoimmune Disorders.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Recombinant Protein Drugs: A 2025 Update.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Nivolumab and ipilimumab combination therapy for melanoma efficacy, safety and clinical integration in metastatic and adjuvant settings.Discover oncology · 2026Review
- Indirect Comparison of the Efficacy of Pembrolizumab Versus Nivolumab as Adjuvant Options for Stage IIB/IIC Melanoma.Targeted oncology · 2026Article
- Baseline neutrophil-to-lymphocyte ratio as a prognostic biomarker in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.Translational cancer research · 2026Article
- The Next Wave of Immunotherapy: A Critical Review of Nanotechnology Strategies for Immune Checkpoint Blockade.Pharmaceutics · 2026Review
- Investigation of the protective effects of hesperidin against nivolumab toxicity in rat testis tissue.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Engineering affibody domains as anti-idiotypic masks for nivolumab-based prodrugs.Protein engineering, design & selection : PEDS · 2026Article
- Advancements in Drug Discovery Techniques for Cancer Treatment: Clinical Progress and Future Directions.Current drug discovery technologies · 2026Review
70 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeted immunotherapy has become the most promising approach for tumor patients. Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, can reverse immune suppression and release T cell activation. Nivolumab, a fully human immunoglobulin G4 PD-1 immune checkpoint inhibitor antibody, blocks PD-1 and promotes antitumor immunity, and it is effective for treating non-small-cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC) and other cancers. The present review summarizes the efficacy and current status of clinical trials of nivolumab and that enabled nivolumab to be investigated in patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.